Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Ning, Y; Gerger, A; Zhang, W; Hanna, DL; Yang, D; Winder, T; Wakatsuki, T; Labonte, MJ; Stintzing, S; Volz, N; Sunakawa, Y; Stremitzer, S; El-Khoueiry, R; Lenz, HJ.
Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.
Mol Cancer Ther. 2014; 13(2):528-539 Doi: 10.1158/1535-7163.MCT-13-0646 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Gerger Armin

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Tumor recurrence after curative resection remains a major problem in patients with locally advanced colorectal cancer treated with adjuvant chemotherapy. Genetic single-nucleotide polymorphisms (SNP) may serve as useful molecular markers to predict clinical outcomes in these patients and identify targets for future drug development. Recent in vitro and in vivo studies have demonstrated that the plastin genes PLS3 and LCP1 are overexpressed in colon cancer cells and play an important role in tumor cell invasion, adhesion, and migration. Hence, we hypothesized that functional genetic variations of plastin may have direct effects on the progression and prognosis of locally advanced colorectal cancer. We tested whether functional tagging polymorphisms of PLS3 and LCP1 predict time to tumor recurrence (TTR) in 732 patients (training set, 234; validation set, 498) with stage II/III colorectal cancer. The PLS3 rs11342 and LCP1 rs4941543 polymorphisms were associated with a significantly increased risk for recurrence in the training set. PLS3 rs6643869 showed a consistent association with TTR in the training and validation set, when stratified by gender and tumor location. Female patients with the PLS3 rs6643869 AA genotype had the shortest median TTR compared with those with any G allele in the training set [1.7 vs. 9.4 years; HR, 2.84; 95% confidence interval (CI), 1.32-6.1; P = 0.005] and validation set (3.3 vs. 13.7 years; HR, 2.07; 95% CI, 1.09-3.91; P = 0.021). Our findings suggest that several SNPs of the PLS3 and LCP1 genes could serve as gender- and/or stage-specific molecular predictors of tumor recurrence in stage II/III patients with colorectal cancer as well as potential therapeutic targets.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Alleles -
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemotherapy, Adjuvant -
Colonic Neoplasms - drug therapy
Colonic Neoplasms - genetics
Colonic Neoplasms - pathology
Disease-Free Survival -
Female -
Fluorouracil - administration & dosage
Gene Frequency -
Genotype -
Humans -
Male -
Membrane Glycoproteins - genetics
Microfilament Proteins - genetics
Middle Aged -
Multivariate Analysis -
Neoplasm Recurrence, Local -
Neoplasm Staging -
Polymorphism, Single Nucleotide -
Prognosis -
Sex Factors -
Time Factors -
Treatment Outcome -

© Med Uni Graz Impressum